Researchers from the IBD clinic at Imelda Hospital participated in a large-scale international study into a new treatment for Crohn’s disease.
Thanks to this research, it became clear how a new type of medication has a rapid, sustained and pronounced positive effect in patients with Crohn’s disease. The renowned medical journal The Lancet will publish two articles this week with the results of the study.
Crohn’s disease is a disease of the gastrointestinal tract that affects approximately 30,000 people in Belgium. In this disease, the gut is attacked by its own immune system. As a result, patients develop complaints such as abdominal pain, diarrhea and blood loss. It usually develops between the ages of 20 and 30 and requires intensive long-term treatment.
Although there are already several treatment options (cortisone, immunosuppressants and biologicals) for Crohn’s disease, many patients do not respond or respond insufficiently to current treatments.
Therefore, there is a continuing need for new drugs. An international study investigated the effects of a new type of medication (risankizumab). This medication blocks a central inflammatory agent that plays a role in both the onset and maintenance of inflammation in Crohn’s disease.
It also has an impact on the permeability of the intestinal wall. The IBD clinic at Imelda Hospital Bonheiden was one of the leading centers in this study.
“Introducing a new class of medication for patients with inflammatory bowel disease is always a huge step forward” explains Peter Bossuyt.
“The results of our study showed that the new treatment has a rapid, sustained and pronounced positive effect in patients with Crohn’s disease. The effect was evident in patients with a recent diagnosis as well as in patients with long-standing and difficult-to-treat Crohn’s disease.”
In addition, the study also showed that not only did the patients’ complaints clearly improve, but that the bowel also recovered quickly after the start of the new treatment.
IBD Clinic Imelda Hospital
The IBD clinic of the Imelda Hospital is part of the Gastroenterology Department and is led by Dr. Peter Bossuyt and Dr. Lieven Pouillon.
The publications in The Lancet can be found on their website.
With more than 1,500 employees, 160 doctors and more than 100 volunteers, we take care of people together. In our dealings with patients and colleagues, we attach great importance to cordiality and friendliness.
We have 502 beds for traditional hospitalization and a day hospital with 94 beds, good for 21,000 admissions and 48,000 day hospital admissions. On an annual basis, 211 000 consultations take place in our hospital.
Providing quality care to so many patients is only possible through enthusiastic teamwork. By providing the most innovative techniques and partly thanks to the continuous training of employees, we are a modern and dynamic hospital.’